GlaxoSmithKline poached Pfizer's RNA and viral vaccines leader Phil Dormitzer, M.D., Ph.D., to shore up its vaccine business as it's lost many research staffers this past year. Parthenon Therapeutics snagged Johnson & Johnson's global head of cell therapy platform and discovery, Tamas Oravecz, Ph.D. And Rafael parted ways with five execs and reinstalled telecom tycoon Howard Jonas as CEO.
Posted on 179
H3 Biomedicine Inc. (H3), a U.S.-based precision medicine research & development subsidiary of Eisai Co., Ltd., today announced a partnership with Flatiron Health, a healthcare technology and services company focused on accelerating cancer research and improving patient care, and Foundation Medicine, a genomic insights company, to expand its use of real-world data in the research and development of drugs for the potential treatment of cancer.
H3 will use Flatiron Health and Foundation Medicine’s extensive, real-world clinico-genomic database (CGDB) to accelerate its research and development efforts as well as aid in the design of clinical trials. The CGDB links comprehensive genomic profiling (CGP) data from patients who underwent CGP testing by a Foundation Medicine assay with clinical outcomes data for patients in the Flatiron Health network.